CereHealth’s Novel SPECT-Analysis Approach to Reveal Brain Abnormalities Validated in Exploration of Medicine Special Issue
DENVER, Nov. 10, 2020 /PRNewswire/ — CereHealth Corporation’s unique approach to analyzing single photon emission computed tomography (SPECT) imaging to reveal brain perfusion abnormalities in neurodegenerative diseases like Alzheimer’s was validated in a manuscript “Going Against the Norm: Validation of a Novel Alternative to Brain SPECT Normative Datasets“ that was recently published in Exploration of Medicine. Historically, quantification has been dependent on comparisons to groups of healthy individuals, but the manuscript instead explored comparisons to a population template, derived from more than 2,000 clinical patient scans in CereHealth’s database. Validation by three testing methods demonstrated that the population template was noninferior to a group of 90 controls despite inclusion of abnormal scans.
CereHealth’s Senior Medical Imaging Engineer Lindsay Quandt, MS, MBA was the lead author of the published manuscript, which was co-authored by Cyrus Raji, MD, PhD of the Mallinckrodt Institute of Radiology at Washington University in St. Louis.
The SPECT approach was first developed for CereHealth’s FDA-cleared CereMetrix® software that uses the population template to measure perfusion levels in SPECT scans. This method is unique to CereHealth’s software application and relies on the company’s proprietary, dynamic database. Defense of their methodology was an integral component of their FDA 510(k) filing and subsequent clearance of the software under the agency’s medical device guidelines in 2018.
“Encouraged by our successful discussions with the FDA, our objective in the manuscript was to share CereHealth’s novel methods with the broader scientific and medical communities to demonstrate the capabilities and performance of our CereMetrix® platform,” said John Kelley, CEO of CereHealth Corporation.
The article is available through Exploration of Medicine, a peer-reviewed, open access online journal promoting articles that provide substantial and novel insights into medicine. Its special issue, guest edited by Dr. Rhoda Au of Boston University, sought papers that featured technological advances that help fill the gaps in fully characterizing Alzheimer’s Disease across the entire life course path. The journal encourages originality, well-designed experiments, and rigorous data in its content and performed an in-depth review during its selection of the paper.
A complete copy of the manuscript may be accessed at A New Frontier for Medicine
About CereHealth Corporation
CereHealth is a data analytics technology company that provides Medical Analytics as a Service, enabling medical providers, research scientists and others serving the healthcare community to quickly make more-informed decisions regarding patient-specific treatments to improve outcomes and patients’ quality of life.
CereHealth’s browser-based platforms offer enhanced insights not previously available and were developed with future artificial intelligence (AI) capabilities in mind. Drawing on a growing database these insights can enable greater diagnosis and treatment accuracy, thereby improving patient outcomes and reducing healthcare costs.
Let us show you how you can transform your radiological or clinical practice by registering for a live demonstration of our software, tailored to your particular needs, at https://ceremetrix.io/request-a-demo/
For Information Contact:
View original content to download multimedia:https://www.prnewswire.com/news-releases/cerehealths-novel-spect-analysis-approach-to-reveal-brain-abnormalities-validated-in-exploration-of-medicine-special-issue-301169334.html
SOURCE CereHealth Corporation
‘It’s not just fitness – everything suffers’: Community heroes reveal fears over lockdown ban on Children
As the seconds ticked by towards sporting wipeout on Wednesday, amateur boxing coach Knox White winced through agonising pain during a flare-up of his degenerative multiple sclerosis.
The wheelchair-bound 46 year-old was struck down twice within a few hours that evening, but nothing was stopping him from taking his final sessions for the youngsters at Hayling Island Community Centre.
“I didn’t need reminding why we all need to be here,” says the former Navy boxer of his packed classes with local youngsters. “After the first week back from lockdown, one of the mums came up to me and said, ‘Knox, I’m so glad we’re back as my son really needs this. I’ve been so worried because one of his friends has taken his life and another one’s attempted to’. I just thought to myself, ‘Oh my God, this is how serious it all is’.”
After a week in which the great and good of elite sport rallied behind The Daily Telegraph’s ‘Keep Kids Active in Lockdown’ campaign, it is thousands of lesser-known heroes carrying the heaviest burden over the weeks ahead.
Tennis coach Stephen Perez is another left worrying about his deprived youngsters. He describes how some of the 10 and 11-year-olds he works with under an LTA initiative in Chatham, Kent, are still rusty from bad diet and lack of exercise during the first lockdown.
“The awful thing is that we know exactly what’s coming,” says Perez, who also runs programmes providing healthy food to his community. “In our community there’s people really struggling with poverty and poor diet. We had some kids coming back with real weight issues to the point where they were struggling to just take part in exercise.
“If you’ve got a fairly contented life, it’s hard to put into perspective how big of a deal these classes are for those in a chaotic setting. For many, they haven’t really got a lot else to look forward to. It’s not just their fitness that suffers – it’s their behaviour, their routine, everything.”
Downing Street has so far resisted pressure to ease restrictions on children’s sport during lockdown, but ‘Keep Kids Active in Lockdown’ struck a chord in sport like few other newspaper campaigns had done before.
It is memories of formative experiences under grass-roots coaches like Perez and White that prompted many of the 130 star names to this week sign up to The Telegraph’s call on Government to offer children a reprieve.
The campaign was launched at 5pm on Monday, with epidemiologists, public health experts and cross-party MPs all warning of a mental and physical health time-bomb as activity levels plunge among under-18s.
Ambiguity and confusion for teachers over the risk of Covid infection inside and outdoors at schools had already led to many schools scaling back contact sports or abandoning them altogether during PE classes.
However, despite scientists insisting outdoor infection risk is significantly lower than in the classrooms, Boris Johnson was unflinching in his determination to make no exceptions to his blanket
Ontario coronavirus models reveal cases growth is much ‘slower’ than anticipated; Alberta changing testing guidelines for children
For more on today’s top stories and the spread of the novel coronavirus across the country, please refer to our live updates below throughout the day, as well as our COVID-19 news hub.
Ontario premier’s constituency closed after COVID-19 outbreak
A statement from the office of Ontario Premier Doug Ford confirms that his constituency office in Etobicoke North has been closed after COVID-19 cases were detected.
“Toronto Public Health has confirmed cases of COVID-19 among staff members of Premier Ford’s constituency office,” the statement reads. “The Premier has not visited the office in the past two weeks and has had no exposure.”
The Etobicoke office is expected to be closed “for the foreseeable future” to allow for deep cleaning of the space.
This comes as Ontario reported 896 new COVID-19 cases on Friday, including 314 cases in Toronto, 173 in Peel, 115 in York Region and 92 in Ottawa.
The province confirmed nine more COVID-19 deaths, bringing the total to 3,127.
A total of 41,008 tests were completed in the last day, with 41,063 tests under investigation.
There are currently 314 people with COVID-19 in Ontario hospitals, including 75 in ICU.
Across the province, 78 long-term care homes have an active outbreak with 421 active cases in residents and 280 staff cases.
Ontario reported 61 new school-related COVID-19 cases, including 40 student cases, four staff cases and 17 cases that haven’t been identified.
Quebec reports more than 950 new cases, 18 new confirmed deaths
Quebec reported 952 new COVID-19 cases on Friday, including 195 cases in Montreal, 151 in Montérégie and 109 in Lanaudière.
The province also confirmed 18 new deaths with four of them occurring in the last 24 hours.
There are currently 515 people with COVID-19 in Quebec hospital, including 81 people in intensive care.
Check out our COVID-19 in Canada topic page for latest news, tips, health updates, cases and more.
LONDON (Reuters) – Traces of COVID-19 can be successfully detected in sewage, helping to give health officials an early warning of local outbreaks of the virus, the British government said on Friday.
A project, originally launched in June, has now proved that fragments of genetic material from the virus can be detected in waste water, indicating if a local community or institution is experiencing a spike in cases.
The government said this would allow health officials to identify large outbreaks especially where there were carriers not displaying any symptoms and to encourage people to get tested or take precautions.
“This is a significant step forward in giving us a clearer idea of infection rates both nationally and locally, particularly in areas where there may be large numbers of people who aren’t showing any symptoms and therefore aren’t seeking tests,” Environment Secretary George Eustice said.
The sewage-testing project has been working successfully in southwest England and has now been extended to 90 wastewater sites covering 22% of England, the government said, adding it aimed to expand it in future.
Reporting by Michael Holden; editing by Stephen Addison
Ongoing coronavirus vaccine trials cannot prove a jab could save lives, one expert has stressed.
An effective immunisation programme has long been hailed as a route back to life as we knew it.
Hopes were raised in July when scientists from the University of Oxford found a vaccine candidate induced “strong antibody and T-cell immune responses up to day 56 of the ongoing trial”.
Antibodies and T-cells make up part of the immune system, helping to prevent an infection from taking hold.
Russia’s controversial vaccine candidate also brought about an immune response within 21 days, however, some experts later called the results “highly unlikely”.
Read more: The risk factors for long COVID
Writing in The BMJ, the journal’s associate editor Dr Peter Doshi stressed vaccine trials are not set up to show a jab reduces the risk of hospitalisation, intensive care admission or death.
Another expert called Dr Doshi’s comments “questionable”, but added “a number of the facts are correct”.
Dr Peter Hotez from the Baylor College of Medicine in Houston has said: “Ideally, you want an antiviral vaccine to do two things.
“First, reduce the likelihood you will get severely ill and go to hospital, and two, prevent infection and therefore interrupt disease transmission.”
While Dr Doshi agrees, he has argued “current [coronavirus] trials are not actually set up to prove either”.
Several coronavirus jab candidates are in phase 3 of clinical development. At an advanced stage, significant results mean the vaccine may be considered for approval by the US Food & Drug Administration (FDA) or the European Medicines Agency.
Read more: Nurses describe working amid pandemic
“None of the trials currently underway are designed to detect a reduction in any serious outcome such as hospitalisations, intensive care use or deaths,” wrote Dr Doshi.
“Nor are the vaccines being studied to determine whether they can interrupt transmission of the virus.”
This echoes concerns voiced after the Oxford scientists released their vaccine results.
The research was hailed as “promising”, “encouraging” and “extremely positive”, however, some also pointed out an immune response may not translate to protection against complications when the coronavirus is encountered outside of a laboratory.
Watch: Can you catch coronavirus twice?
Not all clinical trials have released details on the participants they are analysing.
Dr Doshi claims those we know of are evaluating mild coronavirus cases.
Honing in on the pharmaceutical giant Moderna, Dr Doshi noted how the firm’s executives have listed the rate of hospitalisation as a “key secondary endpoint” of its coronavirus vaccine trial.
Dr Tal Zaks, Moderna’s chief medical officer, later told The BMJ the trial “lacks adequate statistical power to assess that endpoint”.
A lack of statistical power typically means the number of participants is too small or the trial’s duration too short to accurately gauge whether a jab influences a particular outcome.
Early research suggests four out of five coronavirus cases